China's Fosun, US Kite to Start Making Pioneering Lymphoma Drug in Shanghai - (Yicai Global via NewsPoints Desk)

  • Fosun Kite Biotechnology has completed its first production base in Shanghai to make the CAR-T cell immunotherapy Yescarta for the treatment of lymphoma, reported Yicai Global.

  • According to China Securities Journal, the joint venture between Kite Pharma and China's Fosun Pharmaceutical is expected to start producing the gene therapy next year.

  • "We will closely cooperate with drug regulators, promoting an early approval of Yescarta and other cell therapy products to benefit cancer patients in China," said Fosun Kite CEO Richard Wang.

To read more NewsPoints articles, click here.